Skip to main content

Table 1 Clinicopathological characteristics of initial cohort patients

From: Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis

  

Number

(%)

Age

(mean ± SD, years)

52.10 ± 11.10

 

≤50

336

49.9

> 50

338

50.1

Stage

I

290

43.1

II

280

41.5

III

104

15.4

Estrogen receptor

Negative

231

34.3

Positive

443

65.7

Progesterone receptor

Negative

288

42.7

Positive

386

57.3

Operation type

Conservation

395

58.6

Mastectomy

279

41.4

Chemotherapy

None

105

15.6

AC

148

22.0

AC-Taxans

93

13.8

FAC

178

26.4

TAC

58

8.6

Others

92

13.6

Initial hormone therapy

None

195

28.9

Tamoxifen

306

45.4

Aromatase inhibitor

173

25.7

  1. AC Adriamycin and Cyclophosphamide, FAC Fluorouracil, Adriamycin and Cyclophosphamide, TAC Taxan, Adriamycin and Cyclophosphamide
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us